Production (Stage)
Oramed Pharmaceuticals Inc.
ORMP
$2.22
$0.073.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.11% | 151.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 80.81% | 16.38% | |||
| Operating Income | -25.17% | -16.38% | |||
| Income Before Tax | 27.85% | 47.14% | |||
| Income Tax Expenses | 40.38% | -63.28% | |||
| Earnings from Continuing Operations | 25.07% | 48.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -56.52% | |||
| Net Income | 25.00% | 48.07% | |||
| EBIT | -25.17% | -16.38% | |||
| EBITDA | -25.42% | -17.35% | |||
| EPS Basic | 25.99% | 47.78% | |||
| Normalized Basic EPS | -44.60% | 87.21% | |||
| EPS Diluted | 27.98% | 45.01% | |||
| Normalized Diluted EPS | -44.60% | 87.21% | |||
| Average Basic Shares Outstanding | 1.38% | -0.56% | |||
| Average Diluted Shares Outstanding | 1.38% | -0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||